Dr. Sullivan on Practice-Changing COMBI-d and COMBI-v Trials

Ryan J. Sullivan, MD
Published: Thursday, Jul 04, 2019



Ryan J. Sullivan, MD, associate director, Melanoma Program, Massachusetts General Hospital Cancer Center, discusses the results of the COMBI-d and COMBI-v studies, led to changes in practice for patients with BRAF V600-mutant unresectable or metastatic melanoma.

Patients with the BRAF V600 mutation were first treated with the dabrafenib (Tafinlar) plus trametinib (Mekinist) combination in a clinical trial setting in 2010. Patients were able to take full doses and had “remarkable response rates,” according to Sullivan. A cohort of this phase I study found that these agents worked best in combination for this patient population, Sullivan explained.

The results from the phase I trial led to two phase III trials: COMBI-d and COMBI-v. COMBI-d examined dabrafenib plus trametinib versus dabrafenib plus placebo. COMBI-v compared dabrafenib with trametinib versus vemurafenib (Zelboraf) with placebo. Both trials showed higher response rates, progression-free survival, and overall survival with the dabrafenib plus trametinib combination, according to Sullivan. The combination was approved in 2014 to treat patients with BRAF V600-mutant unresectable or metastatic melanoma. These trials changed the standard of care for this patient population, added Sullivan.
SELECTED
LANGUAGE


Ryan J. Sullivan, MD, associate director, Melanoma Program, Massachusetts General Hospital Cancer Center, discusses the results of the COMBI-d and COMBI-v studies, led to changes in practice for patients with BRAF V600-mutant unresectable or metastatic melanoma.

Patients with the BRAF V600 mutation were first treated with the dabrafenib (Tafinlar) plus trametinib (Mekinist) combination in a clinical trial setting in 2010. Patients were able to take full doses and had “remarkable response rates,” according to Sullivan. A cohort of this phase I study found that these agents worked best in combination for this patient population, Sullivan explained.

The results from the phase I trial led to two phase III trials: COMBI-d and COMBI-v. COMBI-d examined dabrafenib plus trametinib versus dabrafenib plus placebo. COMBI-v compared dabrafenib with trametinib versus vemurafenib (Zelboraf) with placebo. Both trials showed higher response rates, progression-free survival, and overall survival with the dabrafenib plus trametinib combination, according to Sullivan. The combination was approved in 2014 to treat patients with BRAF V600-mutant unresectable or metastatic melanoma. These trials changed the standard of care for this patient population, added Sullivan.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x